PubMed HealthSearch

Biomedical subjects

H Fenner

Publications and source records attributed to H Fenner.

At least 19 recordsLinked to original sources

The role of cytokines and their inhibitors in arthritis.

The role of cytokines in inflammatory joint diseases is well documented, especially with regard to tissue destruction and remodelling. In these processes, IL-1 and TNF alpha play a prominent part by stimulating protease production. The regulation of their production, their release and their effects on target cells (e.g. synovial cells, chondrocytes and bone-derived cells) has therefore been the subject of intensive investigations. In this context a new dimension has emerged recently due to the observation of the existence of natural specific cytokine inhibitors. IL-1-ra and the soluble fragments of both TNF receptors--inhibitory by binding to TNF alpha--are natural products. These appear to be the molecules best suited for controlling the imbalance between pro- and anti-inflammatory processes. The use of the recombinant forms of these inhibitors may open new perspectives for therapeutic intervention. The fact that the respective mechanisms of action of receptor antagonists and inhibitory binding proteins differ does not rule out their complementarity. Preliminary experiments with animal models have yielded promising results which should be followed up by clinical trials.

Animals

Nonsteroidal antiinflammatory drugs: benefit/risk evaluation in rheumatic diseases.

Side effects of nonsteroidal antiinflammatory drug (NSAID) therapy are attributed to direct damage by the acidic compounds and to the secondary effects of prostaglandin inhibition. In general, gastrointestinal, skin and central nervous system effects predominate, followed by general adverse hepatic and renal events. Advanced age, female gender, history of gastrointestinal disorders and renal impairment increase the risk of NSAID induced side effects. Pharmacologic modifications that may help minimize side effects include lowered cyclooxygenase inhibitor activity, more stable plasma/tissue concentrations, decreased lipophilicity, avoidance of biliary excretion and renal excretion in inactive form. Prescribing NSAID according to their differing pharmacokinetic profiles may help maximize clinical efficacy and reduce side effects.

Aging

Blood distribution of tenoxicam in humans: a particular HSA drug interaction.

Blood binding of tenoxicam was studied in vitro by equilibrium dialysis. Isolated human plasma proteins and blood cells were checked, and the distribution of the bound form was then calculated. The results showed that tenoxicam is mainly bound to HSA and that binding percentages are not different when measured in plasma (98.4%) and in an HSA solution at physiological concentration (704 microM, 98.15%). In these conditions, within the range of 1-150 microM, the tenoxicam binding percentage remained constant, evidence of a nonsaturable process. When a lower HSA concentration (10 microM) was used, the binding parameters of the tenoxicam interaction were calculated by using the same equilibrium dialysis data, by 3 methods of analysis- a stoichiometric method and site-oriented methods, fixing or not the number of HSA binding sites (n) as integer values. The best fit was observed with the first method, suggesting that two main interactions occurred. The site-oriented method gave lesser fits, the better being observed when n was not fixed. Its value, 1.77, suggest the possibility of two binding sites, one of them not preformed. The effects of known markers of site I, warfarin and apazone, of site II, diazepam and ibuprofen and of palmitic acid showed that tenoxicam is bound simultaneously to both sites I and II. The binding capacity of site I for tenoxicam is enhanced by diazepam: as this compound alone is bound to site II, this result suggests that the two HSA binding sites are not independent.

Bilirubin

Evaluation of the efficacy and safety of NSAIDs. A new methodological approach.

When rheumatic patients were questioned concerning the most desired attributes for a nonsteroidal anti-inflammatory drug (NSAID), the majority of replies related to tolerability. For example; low frequency of gastrointestinal side-effects, safety in the elderly, a low frequency of renal side-effects and a superior anti-inflammatory effect than other drugs available, were all regarded as important NSAID properties. This focus on safety issues by patients is probably due to problems experienced in recent years with non-steroidals on the market. In particular, the withdrawal of benoxaprofen was of major concern for both doctors and patients, and this together with other events over the last few years has not really contributed to an improvement of the relationship between rheumatic patients and doctors. The NSAIDs which have experienced problems and resulted in withdrawal from the market are as follows: benoxaprofen (Coxigon), indoprofen (Flosin), indomethacin (Osmosin, Osmogit), isoxicam (Pacyl) and oxyphenbutazone (Tanderil). Additionally, there were restrictions on the usage of phenylbutazone. This has resulted in the major authorities requiring more data concerning safety issues. The following paper will discuss an overview of the methodology which is now used in the development of a NSAID, using data and procedures obtained from the evaluation of tenoxicam.

Adult

Future trends in non-steroidal anti-inflammatory drug therapy.

In assessing future trends in non-steroidal anti-inflammatory drug (NSAID) development, there are four areas of particular interest: (i) Are the existing classifications still useful? New drugs currently under development may not be covered by the classification as it stands today. (ii) What are the new targets for drug development? The key objectives are to develop drugs with anti-inflammatory and analgesic properties which are not cyclo-oxygenase inhibitors. An area of keen interest is the inhibition of interleukin-1 production. (iii) What are the requirements for new drugs? New agents need to be better tolerated--increasing amounts of data on safety are required by the drug regulatory authorities. (iv) When will patients benefit from the new drugs? Since the development of new drugs remains extremely time-consuming, patients will not benefit from drugs currently undergoing research until at least the mid-1990's. Therefore, since there is no prospect of an alternative to the currently available NSAIDs in the foreseeable future, more theoretical and practical work needs to be undertaken in order for them to be deployed more specifically and selectively.

Anti-Inflammatory Agents

Comparative biochemical pharmacology of the oxicams.

The chronicity of the inflammatory process requires persistent tissue concentrations of non-steroidal anti-inflammatory drugs (NSAIDs), best achieved by using a drug with a long half-life as a once-daily regimen. The oxicams proved to be one of the most promising classes of NSAIDs. They have a similar molecular structure, though substitution of the benzothiazine ring by a thienothiazine system gives tenoxicam a more hydrophilic character. Tenoxicam is thus characterised by lower penetration into tissues requiring more lipophilic properties, e.g. the CNS and skin, and this may explain the lower incidence of adverse reactions at these target organs in comparison with more lipophilic NSAIDs. Poor diffusion into hepatic cells--as a result of a small free fraction, tight binding to proteins and hydrophilic character--explains its low hepatic extraction ratio and--as a consequence--a long half-life. Compared to indomethacin and diclofenac, the oxicams have a moderate inhibitory activity on the synthesis and release of prostaglandins; tenoxicam is half as active as piroxicam, reflecting the correspondent difference in their steady-state plasma concentrations.

Anti-Inflammatory Agents, Non-Steroidal

Comparative biochemical pharmacology of the oxicams.

The chronicity of the inflammatory process requires persistent tissue concentrations of non-steroidal anti-inflammatory drugs (NSAIDs), best achieved by using a drug with a long half-life as a once-daily regimen. The oxicams proved to be one of the most promising classes of NSAIDs. They have a similar molecular structure, though substitution of the benzothiazine ring by a thienothiazine system gives tenoxicam a more hydrophilic character. Tenoxicam is thus characterised by lower penetration into tissues requiring more lipophilic properties, e.g. the CNS and skin and, consequently, a lower incidence of adverse reactions at these target organs. Poor diffusion into hepatic cells--as a result of a small free fraction, tight binding to proteins and hydrophilic character--explains its low hepatic extraction ratio and--as a consequence--a long half-life. Compared to indomethacin and diclofenac, the oxicams have a moderate inhibitory activity on the synthesis and release of prostaglandins; tenoxicam is half as active as piroxicam, reflecting the correspondent difference in their steady-state plasma concentrations.

Anti-Inflammatory Agents, Non-Steroidal

Pharmacokinetics of piroxicam: new aspects.

Some new aspects of the pharmacokinetics of piroxicam have recently become of interest because of the wide use of this compound. Recent studies have provided data on several questions: Are the disposition kinetics of piroxicam different from those of nonsteroidal anti-inflammatory drugs (NSAIDs) with a short half-life, and are the differences in transsynovial distribution relevant to anti-inflammatory activity and significant in the clinical use of these drugs in acute and chronic rheumatic conditions? Are there important differences in the disposition and elimination of piroxicam from patient to patient and in special subgroups such as elderly patients? Is the variation in the half-life of a drug within a given population significant, especially with regard to the rate of metabolic degradation, enterohepatic recirculation, and tubular reabsorption?

Adult

[Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].

Studies of the Clinical Pharmacokinetics of Allopurinol/3rd Communication: Allopurinol/oxipurinol bioavailability and pharmacokinetics following the administration of a controlled release allopurinol formulation. Regarding the results of our studies on the localization of the absorption of allopurinol and the kinetic behavior of allopurinol/oxipurinol following multiple administration the bioavailability and kinetic properties of the drug delivered from controlled release tablets were studied in healthy volunteers. Allopurinol controlled release tablets (Sigapurol CR), containing 200 mg of the drug characterized by rapid absorption and 100 mg characterized by pH-dependent delivery, were identified as a formulation with advantages pharmacokinetic properties.

Adult

[The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].

The rate and extent of allopurinol absorption was studied following its oral ingestion in a "high frequency capsule" which allows the evaluation of the sites of drug absorption. If allopurinol is liberated in the duodenum or upper jejunum its absorption is fast and complete while its liberation in the lower jejunum results in a slow and incomplete absorption. A capacity limited absorption process for allopurinol, suggested from the results of a study on the allopurinol bioavailability from different formulations, could not be proved in the range of single doses between 200 and 600 mg resp. 2.2 to 12.8 mg/kg. AUC- and Cp-values of allopurinol and oxipurinol correspond to the calculated figures in relation to the different doses/kg.

Adult

[The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].

In a pharmacokinetic study with 6 healthy volunteers the parameters for allopurinol and oxipurinol were compared following a single dose of allopurinol and multiple application of the drug. Pharmacokinetic data for allopurinol and oxipurinol are different after single doses and under steady state conditions. The oxipurinol half-life of 17 +/- 5.1 h is prolonged under steady state conditions to 19.7 +/- 5.8 h. Based on the results of this study and on data from different authors the range of 17-21 h is discussed as the most frequent oxipurinol half-life.

Adult

(Photo)chemistry of 5-deazaflavin. A clue to the mechanism of flavin-dependent (de)hydrogenation.

The catalytic action of 5-deazaflavin in the photochemical reduction of flavin and iron proteins [Massey, V. and Hemmerich, P. (1978) Biochemistry, 17, 9--17] is shown to be due to the highly reactive 5-deazaflavosemiquinone. This radical is generated in a complex sequence of reactions, which involves (a) covalent photoaddition of the substrate residue to the deazaflavin, (b) fast secondary photoreaction of this adduct with starting deazaflavin to yield a covalent radical dimer, accompanied by the liberation of the oxidized substrate, and (c) deazaflavin-sensitized cleavage of the radical dimer to the monomers. The structure and properties of this radical (redimerisation or dismutation) and the precursor intermediates as well as the mechanism of the photoreaction are described. Deazaflavins and their natural parent compounds are compared with respect to their different redox behavior and radical stability. The syntheses of 5-deuterated deazaflavins are described and their redox reactions are compared with those of normal deazaflavins.

Chemical Phenomena